|
Video: What is a Stock Split?
|
|
Dare Bioscience is a biopharmaceutical company. Co.'s product, XACIATO vaginal gel, is a single-dose prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. Co.'s portfolio includes three product candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive; Sildenafil Cream, a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring, for the treatment of menopausal symptoms, including vasomotor symptoms, as part of hormone therapy following menopause. According to our DARE split history records, Dare Bioscience has had 0 splits. | |
|
Dare Bioscience (DARE) has 0 splits in our DARE split history database.
Looking at the DARE split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Dare Bioscience shares, starting with a $10,000 purchase of DARE, presented on a split-history-adjusted basis factoring in the complete DARE split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/11/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$6.85 |
|
End price/share: |
$0.49 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-92.85% |
|
Average Annual Total Return: |
-23.25% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$714.90 |
|
Years: |
9.97 |
|
|
|
|
|